MetaVia Inc. reported a net loss of $13.0 million, or $7.35 per share, for the year ended December 31, 2025, compared to a net loss of $27.6 million, or $39.13 per share, for the previous year. The company's operating expenses decreased by 52.4% to $13.7 million, primarily due to lower research and development (R&D) expenses. Revenue remained at $0 for both fiscal years.

R&D expenses for 2025 totaled $6.8 million, a 68.4% decrease from $21.6 million in 2024. This reduction was mainly attributed to decreased activities related to the Phase 2a clinical trial for vanoglipel (DA-1241) and the Phase 1 clinical trial for DA-1726. General and administrative (G&A) expenses also saw a slight decrease of 4.8%, totaling $6.9 million in 2025 compared to $7.3 million in 2024. Other income decreased by 39.6% to $0.7 million, primarily due to lower interest income and a smaller gain from the change in fair value of warrant liabilities.

Key operational developments included the presentation of new Phase 1 and pre-clinical data on DA-1726 at ObesityWeek® 2025, and positive new data from the Phase 2a clinical trial evaluating vanoglipel (DA-1241). The company also announced positive topline data from the non-titrated 48 mg, MAD cohort of its Phase 1 clinical trial of DA-1726. In July 2024, MetaVia entered into an exclusive out-license agreement with MThera for NB-01, a legacy therapeutic program. As of December 31, 2025, the company had eight full-time employees.

Looking ahead, MetaVia plans to start Part 3a and Part 3b of the Phase 1 clinical trial for DA-1726 in April 2026, with data readout expected in the fourth quarter of 2026. The company also expects to finalize the Clinical Study Report (CSR) of the Phase 2a clinical trial for vanoglipel (DA-1241) in the first half of 2026. MetaVia believes that its existing cash and cash equivalents, together with the proceeds from the underwritten public offering in January 2026, will be sufficient to fund its operations into the fourth quarter of 2026. The company will continue to explore financing opportunities and carefully monitor the capital markets.

About MetaVia Inc.

MetaVia Inc. is a biotechnology company focused on developing pharmaceuticals for cardiometabolic diseases, including treatments for MASH and obesity. Its core programs include DA-1241, a GPR119 agonist for liver and diabetes, and DA-1726, a dual GLP-1 and glucagon receptor agonist for weight loss. The company advances its products through clinical trials, leveraging proprietary compounds, licensing agreements, and strategic collaborations in the biotech and pharmaceutical markets.

This description was generated via AI from an annual report. Updated 8 months ago.

About 10-K Filings

A 10-K form is a comprehensive annual report that public companies in the United States must file with the SEC, providing a detailed overview of the company's financial condition, performance, and business strategies.

Key points about the 10-K:

  • Frequency: Filed annually, typically within 60 to 90 days after the end of the company's fiscal year.
  • Content: It includes:
    • Detailed financial statements audited by an independent accounting firm
    • Management's Discussion and Analysis (MD&A) of financial condition and results
    • Description of the company's business, properties, and legal proceedings
    • Risk factors and market risks
    • Executive compensation and corporate governance information
  • Importance: Considered the most comprehensive and important document a public company files with the SEC.
  • Length: Often exceeds 100 pages due to its extensive and detailed nature.

Our Methodology

AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.

Our method:

  1. Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
  2. AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
  3. Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
  4. Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
  5. Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Read more about AssetRoom

Feedback & Corrections

Spot an error or have a suggestion? Contact us.